OR for fetal death according to the anti-EPCR autoantibody levels
. | Cases/controls, n . | Matched OR . | 95% CI . | P for trend . |
|---|---|---|---|---|
| IgM | ||||
| Q1, fewer than 33 AUs | 8/22 | 1 | — | — |
| Q2, 33-52 AUs | 25/23 | 3.1 | 1.0-9.6 | — |
| Q3, 53-70 AUs | 19/21 | 2.6 | 0.8-9.0 | — |
| Q4, more than 70 AUs | 35/21 | 4.4 | 1.4-14.3 | .02 |
| Above p95, more than 99 AUs | 16/3 | 45.2 | 2.9-662.4 | — |
| IgG | ||||
| Q1, fewer than 35 AUs | 18/22 | 1 | — | — |
| Q2, 35-49 AUs | 18/23 | 1.3 | 0.3-4.9 | — |
| Q3, 50-57 AUs | 14/20 | 0.8 | 0.2-2.7 | — |
| Q4, more than 57 AUs | 37/22 | 2.4 | 0.7-8.4 | .12 |
| Above p95, more than 94 AUs | 13/4 | 10.2 | 1.2-86.7 | — |
. | Cases/controls, n . | Matched OR . | 95% CI . | P for trend . |
|---|---|---|---|---|
| IgM | ||||
| Q1, fewer than 33 AUs | 8/22 | 1 | — | — |
| Q2, 33-52 AUs | 25/23 | 3.1 | 1.0-9.6 | — |
| Q3, 53-70 AUs | 19/21 | 2.6 | 0.8-9.0 | — |
| Q4, more than 70 AUs | 35/21 | 4.4 | 1.4-14.3 | .02 |
| Above p95, more than 99 AUs | 16/3 | 45.2 | 2.9-662.4 | — |
| IgG | ||||
| Q1, fewer than 35 AUs | 18/22 | 1 | — | — |
| Q2, 35-49 AUs | 18/23 | 1.3 | 0.3-4.9 | — |
| Q3, 50-57 AUs | 14/20 | 0.8 | 0.2-2.7 | — |
| Q4, more than 57 AUs | 37/22 | 2.4 | 0.7-8.4 | .12 |
| Above p95, more than 94 AUs | 13/4 | 10.2 | 1.2-86.7 | — |
Patients and controls were stratified into quartiles according to the anti-EPCR level. OR for fetal death were calculated in the 2nd (Q2), 3rd (Q3), and 4th (Q4) quartiles, and 95th percentile (p95) compared with those in the 1st (Q1) quartile. Adjustment for variables associated with fetal death included in model 1 analysis was performed. — indicates not applicable.